PTPRC and ovarian cancer: Figure 1 displays representative FACs analysis showing a clear reduction of immune (CD45+: from 72% to 21%) and mesenchymal‐like cells (CD45−/CD90+: from 51% to 13%) in the large fraction and a remarkably increase of ovarian cancer cells (CD45−/EpCAM+ and CD45−/CD24+: 43% to 91% and 49% to 92%, respectively).